Please use this identifier to cite or link to this item:
|Title:||Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin||Authors:||Zhou, J.
|Issue Date:||2010||Citation:||Zhou, J., Ong, C.-N., Shen, H.-M., Hur, G.-M. (2010). Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin. Biochemical Pharmacology 79 (9) : 1242-1250. ScholarBank@NUS Repository. https://doi.org/10.1016/j.bcp.2009.12.014||Abstract:||Andrographolide (Andro), a diterpenoid lactone isolated from a traditional herbal medicine Andrographis paniculata, is known to possess potent anti-inflammatory and anticancer properties. In this study, we sought to examine the effect of Andro on signal transducer and activator of transcription 3 (STAT3) pathway and evaluate whether suppression of STAT3 activity by Andro could sensitize cancer cells to a chemotherapeutic drug doxorubicin. First, we demonstrated that Andro is able to significantly suppress both constitutively activated and IL-6-induced STAT3 phosphorylation and subsequent nuclear translocation in cancer cells. Such inhibition is found to be achieved through suppression of Janus-activated kinase (JAK)1/2 and interaction between STAT3 and gp130. For understanding the biological significance of the inhibitory effect of Andro on STAT3, we next investigated the effect of Andro on doxorubicin-induced apoptosis in human cancer cells. In our study the constitutive activation level of STAT3 was found to be correlated to the resistance of cancer cells to doxorubicin-induced apoptosis. Both the short-term MTT assay and the long-term colony formation assay showed that Andro dramatically promoted doxorubicin-induced cell death in cancer cells, indicating that Andro enhances the sensitivity of cancer cells to doxorubicin mainly via STAT3 suppression. These observations thus reveal a novel anticancer function of Andro and suggest a potential therapeutic strategy of using Andro in combination with chemotherapeutic agents for treatment of cancer. © 2009 Elsevier Inc. All rights reserved.||Source Title:||Biochemical Pharmacology||URI:||http://scholarbank.nus.edu.sg/handle/10635/24575||ISSN:||00062952||DOI:||10.1016/j.bcp.2009.12.014|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 24, 2022
WEB OF SCIENCETM
checked on Jan 24, 2022
checked on Jan 20, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.